SAN DIEGO, Jan. 19, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that it has retained Argot Partners, a corporate and financial communications consultancy, to provide corporate communications services and strategies.
"Apricus has pursued growth through an integrated, global strategy focused on specialty pharmaceutical products addressing a broad array of unmet patient needs," stated Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus Bio. "Our approach delivers value through internal development and commercialization, licensing agreements, geographic partnerships and acquisition, leveraging the strengths of Apricus' commercial products, broad pipeline and proprietary NexACT® technology platform. Retaining Argot Partners demonstrates a commitment to our shareholders and to communicating our vision for building a high-value specialty pharmaceutical company to our target audiences."
"The management team at Apricus has realized tremendous value in the last two years by delivering on a multifaceted product development and commercialization strategy and by building partnerships with some of the most important companies in the life sciences, including Abbott, Bracco, Warner Chilcott, Elis Pharma and Neopharm," stated Andrea F. Rabney, President and Chief Executive Officer of Argot Partners. "Even with this significant progress, the Apricus story has only just begun to unfold. We look forward to working with the Apricus team to ensure that the value created through their vision and execution reaches the global investment community."
About Apricus Biosciences, Inc.
Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT® technology. Apricus Bio's current pipeline includes Vitaros®, approved in Canada for the treatment of erectile dysfunction, Totect® the only drug approved in the US for the treatment of anthracycline extravasation, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare.
The Company also expects to develop and/or acquire and then bring to market additional pharmaceutical products in areas of care that will benefit patient needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and for information on its subsidiary please visit http://www.nexmedusa.com. You can also receive information at http://twitter.com/apricusbio and http://facebook.com/apricusbio.
About Argot Partners
Argot Partners is a corporate and financial communications consultancy that serves public and private companies, investment funds and high net worth individuals.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further develop its and their products and product candidates, to have its products and product candidates approved by relevant regulatory authorities, including Israel, to successfully commercialize such NexACT® products and product candidates and to achieve its development, commercialization and financial goals in Israel and other countries. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.